CymaBay Therapeutics Inc (CBAY) stock is down more than -50% over the past week. CBAY stock has fallen -50.73% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives CBAY stock an overall score of 27 out of a possible 100.
That score is primarily influenced by a short-term technical score of 0. CBAY’s score also includes a long-term technical score of 1. The fundamental score for CBAY is 80. In addition to the average rating from Wall Street analysts, CBAY stock has a mean target price of $21.00. This means analysts expect the stock to add 244.26% over the next 12 months.
What’s Happening with CBAY Stock Today
CymaBay Therapeutics Inc (CBAY) stock has gained 0.74% while the S&P 500 has fallen -0.32% as of 12:22 PM on Wednesday, Jun 12. CBAY is higher by $0.04 from the previous closing price of $6.05 on volume of 3,688,572 shares. Over the past year the S&P 500 is up 3.39% while CBAY has fallen -50.73%. CBAY lost -$1.31 per share in the over the last 12 months.